Professor and Director of Research
Division of Research
Preclinical and Diagnostic Molecular Imaging Laboratory
Dr. Wall is a tenured Professor at the University of Tennessee Graduate School of Medicine where he directs the NIH-funded Amyloidosis and Cancer Theranostics Program focused on the development and translation of biologicals for imaging and therapy of systemic amyloid diseases. Amyloidosis is a family of diseases of increasing recognition, impacting older adults. The amyloid "complex" comprised of clumps of abnormal protein fragments can infiltrate many organs including the heart, nerves and brain. Dr. Wall has over 100 publications, ~13 issued US patents, and has garnered over $10M in grants and research contracts. He and his team have recently started, at UTMC, a new investigator-initiated Phase 1 "first-in-man" clinical trial of a promising new imaging agent for the detection of systemic amyloidosis and they are working to develop novel therapeutic strategies that may help to remove the amyloid complex from the body.
University of Tennessee Medical Center
Human Immunology & Cancer Program
Knoxville, TN (January 1995- April 1997)
University of Essex
Department of Chemistry & Biological Chemistry, Colchester, UK (October 1991- December 1994).
Ph.D conferred July 1995
University of Essex
Department of Biology
Colchester, UK (October 1987-June 1991).
BSc. (Hons.) Biological Sciences, July 1991
Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (June 2009 - present)
Associate Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (June 2003 - June 2009)
Assistant Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (April 1997 - June 2003)
Adjunct Associate Professor, Department of Small Animal Clinical Sciences, University of Tennessee, College of Veterinary Medicine, Knoxville, TN (July 2007 - present)
Director, Preclinical and Diagnostic Molecular Imaging Laboratory, University of Tennessee Graduate School of Medicine, Knoxville, TN (11/2005 - present)
2011 World Molecular Imaging Congress
San Diego, California
Inveon Image of the Year Award 2011
Translational Image of the Year Award 2011
GSM Faculty Award 2011
GSM Spirit Award
University of Tennessee Graduate School of Medicine, June 2011
Amyloid, melanoma and the missing molecular link
University of Uppsala,
Uppsala, Sweden, April 7th 2011
Animal imaging in basic, clinical, and translational research
Biochemistry and Molecular Biology Seminar Series,
The Mayo Clinic,
Rochester, MN. March 1st 2011
2010 World Molecular Imaging Congress
Inveon Image of the Year 2010
Best Presented Image of the Year 2010
Member of the American Association of Immunologists (2001-present)
Society of Nuclear Medicine (May 2007-present)
American Association for Laboratory Animal Science (Gold Membership; 2007- present)
International Society of Amyloidosis (Jan 2008- present)
Honorary member Phi Zeta - The Honor Society of Veterinary Medicine (April 2008-present)
Morgan GJ, Wall JS.
The process of amyloid formation due to monoclonal immunoglobulins. Hematology/Oncology Clinics of North America. 2020 Dec;34(6):1041-1054. Epub 2020 Sep 12.
Wall JS, Heidel RE, Stuckey A, Martin EB, Richey T, Williams A, Foster JS, Whittle B, Fu Y, Powell D, Lands RH, Guthrie S, Kennel SJ.
Detection of systemic AL amyloidosis and differentiation of AL from Attr using 124I-p5+14 PET imaging. Blood. 2020 Nov;136(Sup 1):17–18. Available in Scopus: Dec 2020.
Martin EB, Wall JS.
Looking for amyloid in all the right places. Journal of Cardiac Failure. 2020 Oct 5:S1071-9164(20)31470-6.
Hauptman PJ, Wall JS, Maurer MS.
Disparities, uncertainties and societal cost: Precision medicine and transthyretin amyloidosis. American Journal of Medicine. 2020 Apr 5. [Epub ahead of print]
Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Wall JS, Solomon A, Eisenberger A, Lentzsch S.
One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2019;26(sup1):115-116. Available in PubMed: Jan. 2020.
Jordan TL, Maar K, Redhage KR, Misra P, Blancas-Mejia LM, Dick CJ, Wall JS, Williams A, Dietz AB, van Wijnen AJ, Lin Y, Ramirez-Alvarado M.
Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia. 2019 Dec 3. [Epub ahead of print]
Wall JS, Stuckey A, Martin EB, Richey T, Williams A, Wooliver DC, Macy S, Foster JS, Whittle B, Geldrich R, Powell M, Fu Y, Powell D, Osborne D, Heidel RE, Marine B, Besozzi M, Ramchandren R, Lands RH, Kennel SJ.
Preliminary phase 1 data on the safety and efficacy of a novel PET radiotracer, 124I-p5+14, for imaging systemic amyloidosis. Blood. 2019 Nov;134(Supplement_1):3034-3034.
Richey T, Foster JS, Williams AD, Williams AB, Stroh A, Macy S, Wooliver C, Heidel RE, Varanasi SK, Ergen EN, Trent DJ, Kania SA, Kennel SJ, Martin EB, Wall JS.
Macrophage-mediated phagocytosis and dissolution of amyloid-Like fibrils in mice, monitored by optical imaging. The American Journal of Pathology. 2019 May;189(5):989-998. Epub 2019 Feb 6.
Jackson JW, Hancock TJ, Dogra P, Patel R, Arav-Boger R, Williams AD, Kennel SJ, Wall JS, Sparer TE.
Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screenings. mSphere. 2019 Feb 13;4(1):00586-18.
Nguyen VP, Palanikumar L, Kennel SJ, Alves DS, Ye Y, Wall JS, Magzoub M, Barrera FN.
Mechanistic insights into the pH-dependent membrane peptide ATRAM. Journal of Controlled Release. 2019 Feb 11;298:142-153.
Rowe JA, Morandi F, Osborne DR, Wall JS, Kennel SJ, Reed RB, LeBlanc AK.
Relative skeletal distribution of proliferating marrow in the adult dog determined using 3'-deoxy-3'-[(18) F]fluorothymidine. Anatomia, Histologia, Embryologia. 2019 Jan;48(1):46-52. Epub 2018 Oct 23.
Wall JS, Williams AD, Foster JS, Richey T, Stuckey A, Macy S, Wooliver C, Campagna SR, Tague ED, Farmer AT, Lands RH, Martin EB, Heidel RE, Kennel SJ.
Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America. 2018 Nov 13;115(46):E10839-E10848. Epub 2018 Oct 30.
Martin EB, Williams AD, Heidel RE, Foster JS, Lands RH, Kennel SJ, Wall JS.
A functional assay to identify amyloidogenic light chains. Amyloid. 2018 Mar 23:1-8.
Redhage K, Dick C, Lin Y, Marin-Argany M, Williams A, Wall JS, Ramirez-Alvarado M.
Cardiac light chain amyloidosis, understanding the implications of cellular toxicity in a 3D model. Biophysical Journal. 2018 Feb 2;114(3):498a.
Lin Y, Marin-Argany M, Dick CJ, Redhage KR, Blancas-Mejia LM, Bulur P, Butler GW, Deeds MC, Madden BJ, Williams A, Wall JS, Dietz A, Ramirez-Alvarado M.
Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy. 2017 Dec;19(12):1426-1437. Epub 2017 Oct 14.
Martin EB, Williams A, Richey T, Wooliver C, Stuckey A, Foster JS, Kennel SJ, Wall JS.
Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides. Journal of Translational Medicine. 2017 Dec 11;15(1):247. [Epub ahead of print]
Blancas-Mejia L, Martin EB , Williams A, Wall JS, Ramirez-Alvarado M.
Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients. Biophysical Chemistry. 2017 Nov;230:89-98. Epub 2017 Sep 1.
Wall JS, Williams A, Richey T, Stuckey A, Wooliver C, Scott JC, Donnell R, Martin EB, Kennel SJ.
Specific amyloid binding of polybasic peptides in vivo is retained by beta-sheet conformers but lost in the disrupted coil and all D-amino acid variants. Molecular Imaging and Biology. 2017 Oct;19(5):714-722.
Foster JS, Williams AD, Macy S, Richey T, Stuckey A, Wooliver DC, Koul-Tiwari R, Martin EB, Kennel SJ, Wall JS.
A peptide-Fc opsonin with pan-amyloid reactivity. Frontiers in Immunology. 2017 Sep 4;8:1082.
Wall JS, Foster JS, Martin EB, Kennel SJ.
Pretargeting immunotherapy: A novel treatment approach for systemic amyloidosis. Pharmaceutical Patent Analyst. 2017 Sep;6(5):215-223. Epub 2017 Aug 21.
Wall JS, Kennel SJ, Martin EB.
Dual-energy SPECT and the development of peptide p5+14 for imaging amyloidosis. Molecular Imaging. 2017 May;16:1536012117708705.
Martin EB, Williams A, Wooliver C, Heidel RE, Adams S, Dunlap J, Ramirez-Alvarado M, Blancas-Mejia LM, Lands RH, Kennel SJ, Wall JS.
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. PLoS One. 2017 Mar 28;12(3):e0174152. eCollection 2017.
Piehl DW, Blancas-Mejía LM, Wall JS, Kennel SJ, Ramirez-Alvarado M, Rienstra CM.
Immunoglobulin light chains form an extensive and highly ordered fibril involving the N- and C-termini. ACS Omega. 2017 Feb 28;2(2):712-720. Epub 2017 Feb 27.
Ramirez-Alvarado M, Marin-Argany M, Dick CJ, Blancas-Mejia LM, Misra P, Lin Y, Williams A, Wall JS.
From native to amyloid in the test tube and in cells: A journey of misbehaving antibodies. Biophysical Journal. 2017 Feb;112(3)Sup1:15a.
Wall JS, Williams A, Wooliver C, Martin EB, Cheng X, Heidel RE, Kennel SJ.
Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization. Biochemistry and Biophysics Reports. 2016 Dec;8:89-99. Epub 2016 Aug 11.
Pitt EA, Dogra P, Patel RS, Williams A, Wall JS, Sparer TE.
The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro. Antiviral Research. 2016 Nov;135:15-23. Epub 2016 Sep 25.
Marin-Argany M, Lin Y, Misra P, Williams A, Wall JS, Howell KG, Elsbernd LR, McClure M, Ramirez-Alvarado M.
Cell damage in light chain amyloidosis: Fibril internalization, toxicity and cell-mediated seeding. The Journal of Biological Chemistry. 2016 Sep 16;291(38):19813-25. Epub 2016 Jul 26.
Wall JS. Bacterial biofilms and amyloidosis: Parallels and tools for amyloid detection and removal. Presented at Oak Ridge National Laboratory (Invited Lecture); 2017 Jul 21; Oak Ridge, TN.
Wall JS, Foster JS, Koul R, Williams A, Martin EB, Richey T, Stuckey A, Macy S, Lands R, Hanna W, Kennel SJ. A novel bifunctional peptide-FC-fusion construct for immunotherapy of visceral amyloidosis. Presented at 58th American Society of Hematology Annual Meeting and Exposition; 2016 Dec 3-6; San Diego, CA.
Martin EB, Williams A, Heidel RE, Adams S, Lands R, Hanna W, Kennel SJ, Wall JS. A method to predict the amyloidogenic propensity of light chain proteins by measuring binding to synthetic amyloid fibrils. Presented at 58th American Society of Hematology Annual Meeting and Exposition; 2016 Dec 3-6; San Diego, CA.Top
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2019